Please note that eDoc will be permanently shut down in the first quarter of 2021!      Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Quick Search
My eDoc
Session History
Support Wiki
Direct access to
document ID:

          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Publikationen des W. G. Kerckhoff-Instituts     Display Documents

ID: 474543.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Publikationen des W. G. Kerckhoff-Instituts
Role of epidermal growth factor inhibition in experimental pulmonary hypertension
Authors:Dahal, B. K.; Cornitescu, T.; Tretyn, A.; Pullamsetti, S. S.; Kosanovic, D.; Dumitrascu, R.; Ghofrani, H. A.; Weissmann, N.; Voswinckel, R.; Banat, G. A.; Seeger, W.; Grimminger, F.; Schermuly, R. T.
Date of Publication (YYYY-MM-DD):2010
Title of Journal:Am J Respir Crit Care Med
Issue / Number:2
Start Page:158
End Page:67
Audience:Not Specified
Abstract / Description:RATIONALE: Epidermal growth factor (EGF) and its receptors play a role in cell proliferation and survival and are implicated in the pathobiology of pulmonary arterial hypertension (PAH). OBJECTIVES: To study the role of EGF inhibition on experimental pulmonary hypertension. METHODS: We investigated (1) the effects of three clinically approved EGF receptor (EGFR) antagonists in vitro on rat pulmonary arterial smooth muscle cell proliferation and in vivo on experimental pulmonary hypertension (PH) induced by monocrotaline injection in rats and by chronic hypoxia in mice, and (2) the expression of EGFR in the lung tissues from experimental and clinical PH. MEASUREMENTS AND MAIN RESULTS: The EGFR inhibitors gefitinib, erlotinib, and lapatinib inhibited the EGF-induced proliferation of pulmonary arterial smooth muscle cells. In rats with established PH, gefitinib and erlotinib significantly reduced right ventricular systolic pressure and right ventricular hypertrophy. In addition, the medial wall thickness and muscularization of pulmonary arteries were improved. In contrast, lapatinib did not provide therapeutic benefit. These EGFR antagonists at their highest tolerable dose did not yield significant improvement in right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling in mice with chronic hypoxic PH. Moreover, no significant alteration in the EGFR expression was detected in the lung tissues from patients with idiopathic PAH. CONCLUSIONS: The partial therapeutic efficacy of the EGFR antagonists in animal models of pulmonary hypertension and the absence of significant alteration in EGFR expression in the lungs from patients with idiopathic PAH suggest that EGFRs do not represent a promising target for the treatment of pulmonary hypertension.
Free Keywords:Animals; Antineoplastic Agents/*pharmacology; Cell Division/drug effects; Cell Survival/drug effects; *Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor/*antagonists & inhibitors/genetics; Gene Expression/drug effects; Humans; Hypertension, Pulmonary/pathology/*physiopathology; Male; Mice; Muscle, Smooth, Vascular/drug effects/pathology; Polymerase Chain Reaction; Protein Kinase Inhibitors/*pharmacology; Pulmonary Wedge Pressure/drug effects; Quinazolines/*pharmacology; RNA, Messenger/genetics; Rats; Rats, Sprague-Dawley; Vascular Resistance/drug effects
External Publication Status:published
Document Type:Article
Communicated by:N. N.
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Max Planck Institute for Heart and Lung Research, Parkstrasse 1, 61231 Bad Nauheim, Germany.
Identifiers:ISSN:1535-4970 (Electronic) 1073-449X (Linking)
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.